Skip to main content
Home

Search


NEI on Social Media | Search A-Z | en español | Text size S M L
  • About NEI
    • NEI Research Accomplishments
    • Budget and Congress
    • About the NEI Director
    • History of the NEI
    • NEI 50th Anniversary
    • NEI Women Scientists Advisory Committee (WSAC)
    • Board of Scientific Counselors
    • National Advisory Eye Council (NAEC)
    • Donating to the NEI

    Menu About NEI Block

     Contact Us

     Visiting the NIH Campus

    Mission Statement

    As part of the federal government’s National Institutes of Health (NIH), the National Eye Institute’s mission is to “conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind.”

  • News & Events
    • Events Calendar
    • NEI Press Releases
    • News from NEI Grantees
    • Spokesperson bios
    • Statistics and Data
    • Resources for the media

    Pressroom Contacts

    Dustin Hays - Chief, Science Communication
    dustin.hays@nih.gov

    Kathryn DeMott, Media Relations
    Kathryn.DeMott@nih.gov

    NEI Office of Communications
    (301)496-5248

  • Health Information
    • Clinical Studies
    • Spanish Language Information
    • Publications Catalog
    • Photos and Images
  • Grants and Funding
    • Extramural Research
    • Division of Extramural Science Programs
    • Division of Extramural Activities

    Extramural Contacts

    National Eye Institute
    Division of Extramural Research
    6700B Rockledge Dr., MSC 6914
    Bethesda, MD 20892
    (FedEx, UPS, and other courier services use: Bethesda MD 20817)
    301-451-2020

  • Research at NEI
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Laboratories, Sections and Units
    • eyeGENE
    • Division of Epidemiology and Clinical Applications

    Office of the Scientific Director

    Sheldon S. Miller, Ph.D., Scientific Director
    David M. Schneeweis, Ph.D., Deputy Scientific Director

    Office of the Clinical Director

    Brian P. Brooks, M.D, Ph.D., Clinical Director
    Emily Y. Chew, M.D., Deputy Clinical Director

  • Education Programs
    • National Eye Health Education Program (NEHEP)
    • Diabetic Eye Disease Education Program
    • Glaucoma Education Program
    • Low Vision Education Program
    • Hispanic/Latino Program
    • Vision and Aging Program
    • African American Program
  • Training and Jobs
    • Jobs
    • NEI Summer Intern Program
    • Diversity In Vision Research & Ophthalmology (DIVRO)
    • Student Training Programs

    To search for current job openings visit HHS USAJobs

Home » News » Statements » Statement on the Use of Progressive Addition Lenses vs. Single Vision Lenses to Treat Myopia in Children
Listen

Topics

Age-Related Macular Degeneration (AMD)
AIDS-related eye disease (cytomegalovirus [CMV] retinitis)
Amblyopia
Anophthalmia and Microphthalmia
Appointments
Astigmatism
Audacious Goals Challenge
Awards
Behçet’s Disease of the Eye
Bietti's Crystalline Dystrophy
Blepharitis
Blepharospasm
Cataracts
Clinical Studies
coloboma
Color Blindness
Convergence Insufficiency (CI)
Cornea
Diabetic Eye Disease
Dry Eye
Education Programs
Eye Cancer
Eye Surgery
Floaters
Gene
Glaucoma
Healthy Vision Month
Hispanic/Latino Americans
Histoplasmosis
Hyperopia
Idiopathic Intracranial Hypertension
Infancy
Infectious Eye Disease
Leber Congenital Amaurosis (LCA)
Low Vision
Macular Degeneration
Macular Edema
Macular Hole
Macular Pucker
Myopia
NEI
NEI Remembers
NEI Website
Optic Nerve Disorders
Pink Eye (Conjunctivitis)
Preschool
Rare Diseases
Refractive Errors
Refractive Surgery
Retina
Retinal Disease
Retinitis Pigmentosa
Retinoblastoma
Retinopathy of Prematurity (ROP)
Retinoschisis
Spanish
Spanish
Stargardt Disease
Stem Cells
Usher Syndrome
Uveitis/Inflammatory Eye Disease
Vision Screening
World Sight Day

Statement on the Use of Progressive Addition Lenses vs. Single Vision Lenses to Treat Myopia in Children

Archived Page

The information on this page is archived and provided for reference purposes only. It was current when it was produced, but may now be out-of-date. Persons having difficulty accessing this information may contact kcl@nei.nih.gov for assistance. For reliable, current information on this and other topics, we recommend that you visit the National Eye Institute website index.

03/25/03

Researchers have found that the three-year progression of myopia (nearsightedness) in a large group of ethnically diverse children who wore progressive addition lenses (PALs or no-line bifocals) was slightly less than that of children who wore single vision lenses (SVLs), the conventional treatment for myopia. Although this small difference is greater than what would be expected by chance alone, from a clinical perspective it is not large enough to recommend a change in the way eye care professionals prescribe glasses for children with myopia.

From a research perspective, the results from this clinical trial, called the Correction of Myopia Evaluation Trial (COMET), shed light on mechanisms of myopia and will help to identify risk factors related to progression of myopia in children. These findings appear in the April 2003 issue of Investigative Ophthalmology and Visual Science. The study was funded by the National Eye Institute (NEI), part of the Federal government's National Institutes of Health.

Data were collected from 469 African-American, Asian, Caucasian, and Hispanic children at four clinical centers in the United States. All children had moderate amounts of myopia in both eyes and were six through 11 years old at the start of the study. Eligible children were randomly assigned to receive either PALs (n = 235) or SVLs (n = 234). Retention of children in COMET was outstanding, with 462 of the 469 children (98.5 percent) completing the three-year visit. The main result was that the difference in progression of myopia between the PAL and SVL groups after three years was 0.20 diopters (D). Increases in the overall length of children's eyes paralleled the changes in the amount of myopia in both the PAL and SVL groups.

The size of the treatment effect in COMET is similar to that reported in other recent lens studies for myopia control, even though there are differences in the study designs. While this modest treatment effect is not large enough to recommend a change in clinical practice for all children with myopia, results of COMET suggest that there may be some children for whom PALs may be beneficial for slowing the progression of myopia. This will require further study.

Myopia is a significant public health problem, affecting at least 25 percent of adults in the United States and a much higher percentage of people in Asia. Recent data suggest that these percentages are increasing. In addition to blurring vision at distance, high myopia is a predisposing factor for retinal detachment, myopic retinopathy, and glaucoma, thus contributing to loss of vision and blindness that cannot be corrected with glasses or contact lenses. The high prevalence of myopia and its prominence as a public health problem emphasize the importance of understanding the mechanisms of development and finding effective ways to prevent or slow its progression.

A key observation from COMET is that the treatment effect occurred in the first year and was sustained at the same level over the next two years. The early effect of an intervention to slow myopia also has appeared in results from previous studies of lens and drug therapies, although it has not been addressed in other reports. This result has implications for mechanisms of myopia and will be important for guiding future attempts to develop treatments for myopia.

A major advance in the last five years of myopia laboratory research supported by the NEI has been the demonstration that the growth of the eye and the development of refractive state (e.g., myopia) are guided by visual feedback. Studies have shown that images not focused on the retina guide the eye to grow to correct for this lack of focus. Research on animals funded by the NEI shows that there is a cascade of signaling mechanisms within the eye and, guided by visual feedback, these signals control the growth of the eye and its refractive state. Many studies have documented that the eyes of animals exposed to continuous retinal defocus become myopic.

The rationale for COMET was based in part on these findings. Retinal defocus resulting from poor accommodation (focusing of the eyes) when children with low amounts of recent onset myopia are engaged in close work may be a stimulus for increased eye growth and myopia progression. PALs may slow progression of myopia in these children by reducing retinal defocus. Results from COMET provide some support for the rationale. The difference between the PAL and SVL groups was greater in children with poorer accommodative response and lower amounts of myopia at the start of the study. An additional exploratory analysis combining these two factors showed a three-year treatment effect of PALs of 0.55D in children with both poor accommodative response and a low level of myopia at the start of COMET.

The COMET data on progression of myopia in a large, ethnically diverse group of children complement other ongoing NEI-funded studies that are investigating factors related to development of myopia in infants, young children, and middle-aged adults. COMET has met one of the NEI program objectives by evaluating a treatment for slowing the progression of myopia. Additional analyses of the data will further address the objectives by identifying risk factors for progression of myopia and abnormal eye growth.

In summary, results of COMET suggest that PALs should not be prescribed routinely for slowing myopia progression in children. However, they still may be prescribed for other ocular conditions. Findings from this study will influence ongoing and future studies of myopia interventions and mechanisms of eye growth.

References: 
Full-text article (PDF) Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D, Leske MC, Manny R, Marsh-Tootle W, Scheiman M, and the COMET Group: A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. IOVS 44: 1492-1500, 2003.
  • NEI Home
  • Contact Us
  • A-Z Site Map
  • NEI on Social Media
  • Information in Spanish (Información en español)
  • Website, Social Media Policies and Other Important Links
  • NEI Employee Emergency Information
  • NEI Intranet (Employees Only)
  • Department of Health and Human Services
  • The National Institutes of Health
  • USA.gov

*PDF files require the free Adobe® Reader® software for viewing.

Technical questions about this website can be addressed to the NEI Website Manager.